With more than 70 developing countries in the consortium, Cavidi said that the agreement is a significant step in making viral load monitoring more accessible to HIV-positive patients in the developing world.
Viral load monitoring is essential for the proper management of HIV-positive patients being treated with antiretroviral drugs (ARVs). The test helps doctors use ARVs more effectively to extend a patient’s length and quality of life, limit the development of viral resistance and minimize waste of medication.
Martyn Eales, Cavidi’s CEO, said: “Viral load testing is an essential part of HIV management. As more people in the developing world gain access to ARVs, it’s important that access to viral load testing keeps pace. It’s Cavidi’s goal to make monitoring more accessible in all countries. I am very pleased with our partnership with President Clinton’s foundation because it brings us closer to reaching that goal.”